May 07, 2015 08:55 PM EDT
Gamers all over the world are squealing in delight following the news that the Oculus Rift Virtual Reality consumer headset has finally been scheduled for release in early 2016. The announcement of a consumer model was first promised in November of 2012 and after two and a half years' anticipation, it appears the dream of a virtual reality headset built for everyday consumers might finally be coming true.
The headset is the brainchild of the young entrepreneur, Palmer Luckey, who developed the idea through countless hours of tinkering with electronics. His prototype, which he vetted on 3D discussion forums, was soon seen by John Carmack. Known as the father of the first-person shooter, Carmack recognized the potential of Luckey's design and after presenting the concept to other influential members in the biz, he and Luckey were off and running.
And now, three years later, Luckey's ingenious gadget might finally be available to gamers everywhere.
In a recent press release by Oculus, they tout the headset's cutting edge technology, claiming the Rift, "delivers on the dream of consumer VR with compelling content, a full ecosystem, and a fully-integrated hardware/software tech stack designed specifically for virtual reality." Not only is the headset more ergonomically advanced, it also contains an improved tracking system that enables the wearer to sit, stand, and move about within the game; actions that were previously inhibited by limitations in technology.
Oculus claims their virtual reality technology will transform not only gaming, but film, entertainment, and the communication industry as well. So stay tuned for more details.
1. Nov 27, 2018
3. Sep 17, 2018
Study: Earth's oldest animals formed complex ecological communities
4. Aug 21, 2018
Study: Length of opioid prescription spell highest risk for misuse after surgery
2. Jul 27, 2018
Targeting headaches and tumors with nano-submarines
3. Jul 26, 2018
Researchers develop a new method to detect nucleation
4. Jul 26, 2018
New system can identify drugs to target 'undruggable' enzymes critical in many diseases